Literature DB >> 20848225

Expression and clinical significance of hepatoma-derived growth factor as a prognostic factor in human hilar cholangiocarcinoma.

Yan-feng Liu1, Rui Zhao, Sen Guo, Xian-qiang Wang, Pei-long Lian, Yue-guang Chen, Ke-sen Xu.   

Abstract

BACKGROUND: Overexpressions of hepatoma-derived growth factor (HDGF) and vascular endothelial growth factor (VEGF) play important roles in the development and progression of cancers. This study investigates the expression of HDGF combined with VEGF, their correlation with clinicopathologic features, and their prognosis in human hilar cholangiocarcinoma.
MATERIALS AND METHODS: The expressions of HDGF and VEGF were analyzed by immunohistochemistry using the streptavidin peroxidase complex method for 58 patients with hilar cholangiocarcinoma receiving surgery. Their correlation with clinicopathologic features was then investigated. The relationships between them and the survival time of patients were retrospectively analyzed.
RESULTS: HDGF and VEGF were positively expressed in 27 (46.6%) and 42 (72.4%) patients, respectively. HDGF and VEGF had a positive correlation (r = 0.370, P = 0.004) in the Spearman rank correlation analysis. HDGF expression was associated with gender and histological type. Patients with positive HDGF expression had a significantly poorer overall survival rate than those with negative HDGF expression (35.7 vs. 73.3%, P = 0.003). Multivariate analysis showed that HDGF expression is an independent prognostic factor.
CONCLUSIONS: HDGF expression significantly correlates with VEGF expression and is a valuable prognostic factor for human hilar cholangiocarcinoma.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20848225     DOI: 10.1245/s10434-010-1303-x

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  14 in total

1.  Upregulation of nucleus HDGF predicts poor prognostic outcome in patients with penile squamous cell carcinoma bypass VEGF-A and Ki-67.

Authors:  Dawei Li; Zhen Han; Jikai Liu; Xiang Zhang; Juchao Ren; Lei Yan; Hainan Liu; Zhonghua Xu
Journal:  Med Oncol       Date:  2013-09-03       Impact factor: 3.064

2.  Hepatoma-derived growth factor: a novel prognostic biomarker in intrahepatic cholangiocarcinoma.

Authors:  Sen Guo; Hong-da Liu; Yan-Feng Liu; Lei Liu; Qiang Sun; Xi-Jun Cui
Journal:  Tumour Biol       Date:  2014-09-28

3.  Tumorigenesis and prognostic role of hepatoma-derived growth factor in human gliomas.

Authors:  Shu-Shong Hsu; Chih-Hao Chen; Guei-Sheung Liu; Ming-Hong Tai; Jyh-Seng Wang; Jain-Ching Wu; Mei-Lang Kung; Elsa C Chan; Li-Feng Liu
Journal:  J Neurooncol       Date:  2011-10-26       Impact factor: 4.130

4.  Identification of hepatoma-derived growth factor as a potential prognostic and diagnostic marker for extrahepatic cholangiocarcinoma.

Authors:  Yuxia Han; Wenxia Zhang; Yanfeng Liu
Journal:  World J Surg       Date:  2013-10       Impact factor: 3.352

5.  Overexpressions of CK2β and XIAP are associated with poor prognosis of patients with cholangiocarcinoma.

Authors:  Fan Zhou; Jiewei Xu; Guoping Ding; Liping Cao
Journal:  Pathol Oncol Res       Date:  2013-07-05       Impact factor: 3.201

6.  The expression of hepatoma-derived growth factor in primary central nervous system lymphoma and its correlation with angiogenesis, proliferation and clinical outcome.

Authors:  San-Zhong Li; Yong-Bo Zhao; Wei-Dong Cao; Yan Qu; Peng Luo; Hai-Ning Zhen; Xiao-Yan Chen; Zhi-Feng Yan; Zhou Fei
Journal:  Med Oncol       Date:  2013-06-15       Impact factor: 3.064

7.  The expression and clinical significance of HDGF in osteosarcoma.

Authors:  Zhiguo Chen; Shenghai Qiu; Xiaofei Lu
Journal:  Onco Targets Ther       Date:  2015-09-09       Impact factor: 4.147

8.  Hepatoma-derived growth factor predicts unfavorable prognosis of epithelial ovarian cancer.

Authors:  Xue-Jun Liu; Wen-Lian Liu; Fang-Mei Yang; Xiao-Qing Yang; Xiao-Fei Lu
Journal:  Onco Targets Ther       Date:  2015-08-13       Impact factor: 4.147

9.  Downregulated expression of hepatoma-derived growth factor inhibits migration and invasion of prostate cancer cells by suppressing epithelial-mesenchymal transition and MMP2, MMP9.

Authors:  Feilong Yang; Nengwang Yu; Hui Wang; Cong Zhang; Zhao Zhang; Yanxiang Li; Dawei Li; Lei Yan; Hainan Liu; Zhonghua Xu
Journal:  PLoS One       Date:  2018-01-04       Impact factor: 3.240

10.  Hepatoma-derived growth factor and nucleolin exist in the same ribonucleoprotein complex.

Authors:  Stephanie Bremer; Katharina Klein; Angela Sedlmaier; Mekky Abouzied; Volkmar Gieselmann; Sebastian Franken
Journal:  BMC Biochem       Date:  2013-01-10       Impact factor: 4.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.